At an optimal concentration of 0.2 μM, cycloastragenol (CAG) — a triterpenoid extracted from Astragalus membranaceus — extended mean lifespan in C. elegans by 30.64% while simultaneously reducing lipofuscin accumulation, improving locomotion, and enhancing resistance to Pseudomonas aeruginosa infection. Mechanistically, CAG drove nuclear translocation of the FOXO transcription factor DAF-16, elevated antioxidant enzyme activity, and — critically — activated the p38 MAPK cascade (SEK-1/PMK-1/SKN-1) while suppressing the Insulin/IGF-1 Signaling (IIS) pathway, entirely independent of telomerase activity.
CAG has long been marketed as a telomerase activator, making this telomerase-independent longevity mechanism genuinely novel and scientifically significant. The IIS/DAF-16 axis is one of the most conserved longevity pathways from nematodes to mammals, and concurrent p38 MAPK activation for innate immune enhancement adds a second, complementary layer rarely demonstrated for a single botanical compound. This positions CAG alongside rapamycin and metformin as compounds targeting core aging networks rather than single endpoints.
However, the limitations here are substantial. C. elegans are invertebrates with no adaptive immune system and vastly simplified metabolism; a 30% lifespan extension in worms has historically translated poorly to mammals. The study used mutant strain validation, which is rigorous for mechanism, but human pharmacokinetics, bioavailability, and safe dosing for CAG remain poorly characterized. This is confirmatory-plus: it sharpens mechanistic understanding significantly, but mammalian validation is the essential next step before any longevity claim for humans is warranted.
